Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer
2008-004637-16Phase 2Completed
- Sponsor
- Fondazione Giscad per la Ricerca sui Tumori
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in pancreatic adenocarcinoma (PDAC), sponsored by Fondazione Giscad per la Ricerca sui Tumori. Primary endpoints: Overall Response Rate and Safety. Started Apr 2012; status: completed.
02
Drugs
irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2008-004637-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004637-16.